Montara Therapeutics Announces Development Candidate for First BrainOnly™-Enabled Program in TSC-Related Epilepsy and Appoints Chief Business Officer
December 10, 2025
Montara Therapeutics, a preclinical stage biotechnology company pioneering brain-selective therapies for central nervous system (CNS) diseases, today announces the naming of its first development candidate for the BrainOnly platform.